Long-term nerandomilast for pulmonary fibrosis follow-up
Treatments studied
Part of Lungs & breathing clinical trials.
This trial offers long-term treatment with nerandomilast for people with pulmonary fibrosis who already completed an earlier nerandomilast study. It aims to see how safe and effective the drug is over a longer period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have finished the full treatment in an earlier nerandomilast study without stopping the drug early.
- You cannot have had recent suicidal thoughts or actions.
- You cannot have severe depression as judged by the study doctor.
- You cannot have a new cancer (except certain treated skin cancers).
- You cannot have a scheduled lung transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study continues treatment for people who already completed a previous study with an Avalyn inhaled antifibrotic drug. It aims to check the long-term safety of the medication for patients with certain types of lung scarring.
This trial tests an inhaled form of nintedanib (a drug that helps slow lung scarring) for people with idiopathic pulmonary fibrosis (IPF). It may be an option for those newly diagnosed or already on stable treatment.
This trial tests the safety of a new inhaled medicine. You must be a healthy nonsmoker, have normal lung function, and agree to avoid certain medications and foods.
This trial tests a new medicine called HSK44459 for people with progressive pulmonary fibrosis (PPF). It aims to see if the drug can help slow lung damage and improve breathing. You may join if you are not taking certain other fibrosis drugs or have been on a stable dose for at least 12 weeks.
This trial tests an oral medicine called rentosertib for people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. It aims to see if the drug can help slow the disease. You may qualify if you are 40 or older, have a confirmed IPF diagnosis with certain lung function levels, and are either on a stable dose of standard IPF meds or not taking them.
This study looks at how patients with pulmonary fibrosis (lung scarring) make decisions about stopping or continuing anti-fibrosis medications, especially if they have had side effects. It may help doctors and patients understand the best treatment choices.
Hear when a new Idiopathic Pulmonary Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.